DK0697866T3 - Højdosisformuleringer - Google Patents

Højdosisformuleringer

Info

Publication number
DK0697866T3
DK0697866T3 DK94916722T DK94916722T DK0697866T3 DK 0697866 T3 DK0697866 T3 DK 0697866T3 DK 94916722 T DK94916722 T DK 94916722T DK 94916722 T DK94916722 T DK 94916722T DK 0697866 T3 DK0697866 T3 DK 0697866T3
Authority
DK
Denmark
Prior art keywords
high dose
dose formulations
mycophenolic acid
mycophenolate mofetil
formulations
Prior art date
Application number
DK94916722T
Other languages
Danish (da)
English (en)
Inventor
Stephen Berry
Paul Joseph Jarosz
Charles Lee
Jung-Chung Lee
Glenn Jay Samuels
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Application granted granted Critical
Publication of DK0697866T3 publication Critical patent/DK0697866T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94916722T 1993-05-13 1994-05-10 Højdosisformuleringer DK0697866T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/061,656 US5455045A (en) 1993-05-13 1993-05-13 High dose formulations
PCT/US1994/005196 WO1994026266A1 (en) 1993-05-13 1994-05-10 High dose formulations

Publications (1)

Publication Number Publication Date
DK0697866T3 true DK0697866T3 (da) 2000-04-17

Family

ID=22037233

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94916722T DK0697866T3 (da) 1993-05-13 1994-05-10 Højdosisformuleringer

Country Status (23)

Country Link
US (3) US5455045A (de)
EP (1) EP0697866B1 (de)
JP (1) JP3584037B2 (de)
KR (1) KR100296214B1 (de)
CN (1) CN1045884C (de)
AT (1) ATE187067T1 (de)
AU (1) AU674960B2 (de)
BR (2) BR9406604A (de)
CZ (1) CZ285297B6 (de)
DE (1) DE69421918T2 (de)
DK (1) DK0697866T3 (de)
ES (1) ES2138661T3 (de)
FI (1) FI114286B (de)
GR (1) GR3032021T3 (de)
HU (2) HU226470B1 (de)
IL (1) IL109639A (de)
NO (1) NO308828B1 (de)
NZ (1) NZ266683A (de)
PL (1) PL175583B1 (de)
PT (1) PT697866E (de)
RU (1) RU2135182C1 (de)
TW (1) TW434010B (de)
WO (1) WO1994026266A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2063791C (en) * 1989-08-17 2000-12-19 Michael John Story Hard gelatine capsule containing fat-soluble nutrients.
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
EP0818990A1 (de) * 1995-04-03 1998-01-21 Abbott Laboratories Homogene mischungen aus niedrigschmelzenden arzneistoffen und additiven zur verzögerten wirkstoffeingabe
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
NZ520780A (en) 2000-02-18 2006-04-28 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
WO2001062711A2 (en) 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
ATE365737T1 (de) * 2002-12-05 2007-07-15 Cv Therapeutics Inc Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren
NZ541069A (en) * 2003-01-03 2008-09-26 Cv Therapeutics Inc Piperazine derivatives as fatty acid oxidation inhibitors
WO2004069818A1 (en) * 2003-01-17 2004-08-19 Cv Therapeutics Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
CA2530376A1 (en) * 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
CA2550257A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
WO2005105768A2 (en) * 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) * 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
TWI322147B (en) * 2004-07-20 2010-03-21 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium
US7271169B2 (en) * 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
CN100393312C (zh) * 2005-04-18 2008-06-11 吴建梅 霉酚酸或其类似物的软胶囊及其制备方法
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
JP2009542605A (ja) * 2006-07-06 2009-12-03 アレス トレーディング ソシエテ アノニム アニリノ−ピリミジンの経口医薬組成物、その製法、及びその使用
EP2051583A4 (de) * 2006-08-16 2011-09-14 Aspreva Pharmaceuticals Ltd Zusammensetzungen und verfahren zur behandlung von gefäss-, autoimmun- und entzündungserkrankungen
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
EP2117549A1 (de) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Verwendung von ranolazin zur behandlung koronarer mikrovaskulärer erkrankungen
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
AR068745A1 (es) * 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
JP2011527339A (ja) * 2008-07-09 2011-10-27 アスプレバ インターナショナル リミテッド 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液
US9012192B2 (en) * 2008-08-26 2015-04-21 Intelligentnano Inc. Ultrasound enhanced growth of microorganisms
EP2326716B1 (de) 2008-08-26 2015-04-22 Intelligentnano Inc. Verstärktes tierzellenwachstum anhand von ultraschall
US8962290B2 (en) 2008-08-26 2015-02-24 Intelligentnano Inc. Enhanced animal cell growth using ultrasound
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
EP3351240B1 (de) * 2009-05-19 2019-04-10 Celgene Corporation Formulierungen von 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion
EP2515880B1 (de) 2009-05-28 2019-11-27 Lupin Limited Neuartige pharmazeutische zusammensetzungen mit ranolazin
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
US12558675B2 (en) 2020-09-27 2026-02-24 China Petroleum & Chemical Corporation Disproportionation and transalkylation catalyst, and preparation and application thereof
CN114456835B (zh) 2020-10-22 2023-06-06 中国石油化工股份有限公司 一种汽油组分的处理系统和处理方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
JPS5542995B2 (de) * 1972-02-24 1980-11-04
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
US4145918A (en) * 1976-09-07 1979-03-27 Akzona Incorporated Freeze-thaw indicator
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CA1125698A (en) * 1978-03-09 1982-06-15 Masaru Yoshida Process for preparing a polymer composition
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
DE3613799C1 (de) * 1986-04-24 1987-09-03 Nattermann A & Cie Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US5175000A (en) * 1987-06-30 1992-12-29 Vipont Pharmaceutical, Inc. Free amine benzophenanthridine alkaloid compositions
US4936074A (en) * 1988-11-17 1990-06-26 D. M. Graham Laboratories, Inc. Process for preparing solid encapsulated medicament
AU5419690A (en) * 1989-03-31 1990-11-05 Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
EP0497977B1 (de) * 1989-10-26 1995-03-15 Nippon Shinyaku Company, Limited Zubereitung für den magen
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
ATE166228T1 (de) * 1990-08-10 1998-06-15 Anormed Inc Immunosuppressive zusammensetzungen
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5467037A (en) * 1994-11-21 1995-11-14 International Business Machines Corporation Reset generation circuit to reset self resetting CMOS circuits

Also Published As

Publication number Publication date
BR1100723A (pt) 2000-04-18
KR100296214B1 (ko) 2001-10-24
HU211270A9 (en) 1995-11-28
HU9503224D0 (en) 1996-01-29
BR9406604A (pt) 1996-01-02
GR3032021T3 (en) 2000-03-31
NO954546L (no) 1995-11-10
KR960702304A (ko) 1996-04-27
CZ285297B6 (cs) 1999-06-16
FI114286B (fi) 2004-09-30
TW434010B (en) 2001-05-16
JPH08510254A (ja) 1996-10-29
PL311654A1 (en) 1996-03-04
IL109639A (en) 1998-02-08
JP3584037B2 (ja) 2004-11-04
CN1122571A (zh) 1996-05-15
AU674960B2 (en) 1997-01-16
DE69421918T2 (de) 2000-03-30
NO308828B1 (no) 2000-11-06
CZ295495A3 (en) 1996-02-14
HU226470B1 (en) 2008-12-29
EP0697866B1 (de) 1999-12-01
NZ266683A (en) 1996-08-27
PT697866E (pt) 2000-04-28
WO1994026266A1 (en) 1994-11-24
ATE187067T1 (de) 1999-12-15
HUT72978A (en) 1996-06-28
EP0697866A1 (de) 1996-02-28
ES2138661T3 (es) 2000-01-16
FI955439A0 (fi) 1995-11-10
CN1045884C (zh) 1999-10-27
DE69421918D1 (de) 2000-01-05
PL175583B1 (pl) 1999-01-29
NO954546D0 (no) 1995-11-10
US5554384A (en) 1996-09-10
FI955439L (fi) 1995-11-10
US5472707A (en) 1995-12-05
AU6830194A (en) 1994-12-12
RU2135182C1 (ru) 1999-08-27
US5455045A (en) 1995-10-03
IL109639A0 (en) 1994-08-26

Similar Documents

Publication Publication Date Title
NO954546D0 (no) Höydosepreparater
ES503011A0 (es) Un procedimiento para la preparacion de una formulacion por-tadora de farmacos,biodegradable y magneticamente localiza- ble
NO177177C (no) Fremgangsmåte for fremstilling av en flytende doseringsform for oral administrasjon av en farmasöytisk substans
IT8921132A0 (it) Inalatore per medicamenti in capsule.
FI913248A0 (fi) Kontrollerat frigoerande fast farmaceutisk doseringsform.
NO863670L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat av et hydrofobt legemiddel.
DE3784594D1 (de) Mikrokapseln enthaltende pharmazeutische zusammensetzungen.
IT8621358A0 (it) Composizione farmaceutica adattivita' analgesica.
FR2714594B3 (fr) Structure de diffuseur pour infusion de plantes médicinales.
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
IT9047659A1 (it) Composizione farmaceutica contenente ranitidina sotto forma di capsule di gelatina.
DE3583765D1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
ES509179A0 (es) "un metodo de fabricacion de una composicion farmaceutica de liberacion retardada en forma de pastillas que contiene como agente terapeutico ibuprofen o flurbiprofen".
DE3578597D1 (de) 4-phenylphthalazin-derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
CA2162670A1 (en) High dose formulations of mycophenolate mofetil, mycophenolic acid and ranolazine
ATE8460T1 (de) Pharmazeutische praeparate und deren herstellung.
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
LV10917A (lv) Bambuterina pielietojums lipidu saturu pazeminosu farmaceitisku kompoziciju pagatavosanai
IT1150194B (it) Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva
IT8026232A0 (it) Composizioni farmaceutiche. derivato dell'alfa-mercapto propionilglicina ad attivita'terapeutica, procedimento per lasua preparazione e relative
DE3670083D1 (de) Pharmazeutische pyrrolizidinverbindungen und -zusammensetzungen und ihre herstellung.
IT8422445A0 (it) Composti antiinfiammatori ed analgesici, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT8819541A0 (it) Composizione farmaceutica per somministrazione nasale.
IT8219453A0 (it) Composizione farmaceutica adattivita' analgesica, antipiretica e antiinfiammatoria e procedimento per la preparazione del principio attivo.
IT8619383A0 (it) Nuovi composti ad attivita'colinergica, procedimento per laloro preparazione e relative composizioni farmaceutiche.